CellPro granted partial stay:
This article was originally published in Clinica
Executive Summary
CellPro has been granted a partial stay of the injunction covering its Ceprate SC stem cell concentration system, which has been found to infringe patents held by Johns Hopkins University. The product is licensed to Baxter and Becton Dickinson. A US court of appeals ruling has suspended provisions requiring CellPro to phase down non-US sales of disposable products for use with Ceprate by 25% a quarter in the 12 months to July 1998, pending review of the case on appeal. Total product sales were up by 27% to $8.1 million in the nine months. Net loss for the nine months was $16.6 million, down from $16.8 million.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.